Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma

<p>Abstract</p> <p>Background</p> <p>Toceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in an additional 50-60% of dogs. T...

Full description

Bibliographic Details
Main Authors: Urie Bridget K, Russell Duncan S, Kisseberth William C, London Cheryl A
Format: Article
Language:English
Published: BMC 2012-05-01
Series:BMC Veterinary Research
Subjects:
Online Access:http://www.biomedcentral.com/1746-6148/8/67
_version_ 1818664044104515584
author Urie Bridget K
Russell Duncan S
Kisseberth William C
London Cheryl A
author_facet Urie Bridget K
Russell Duncan S
Kisseberth William C
London Cheryl A
author_sort Urie Bridget K
collection DOAJ
description <p>Abstract</p> <p>Background</p> <p>Toceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in an additional 50-60% of dogs. The basis for the observed responses to toceranib is not known. The purpose of this study was to evaluate AGASACA and TC samples for the expression and activation of VEGFR2, PDGFRα, PDGFRβ, KIT and RET to assess whether dysregulation of these receptor tyrosine kinases (RTKs) may contribute to the biologic activity of toceranib.</p> <p>Results</p> <p>mRNA for VEGFR2, PDGFRα/β, KIT and RET was detected in all AGASACA samples. mRNA for VEGFR2, PDGFRα/β, and KIT was detected in all TC samples, while mRNA for RET was amplified in 10/15 samples. No phosphorylation of VEGFR2, PDGFRα/β, or KIT was observed on the arrays. However, phosphorylation of RET was detected in 54% of the primary AGASACA and 20% of TC. VEGFR2 was expressed in 19/24 primary and 6/10 metastatic AGASACA and 6/15 TC samples. KIT was present in 8/24 primary and 3/10 metastatic AGASACA and 9/15 TC samples. PDGFRα expression was noted in all tumor samples. In contrast PDGFRβ expression was found in only a few tumor samples but was evident in the stroma of all tumor specimens.</p> <p>Conclusions</p> <p>Known targets of toceranib are expressed in both AGASAC and TC. Given the observed expression of VEGFR and PDGFRα/β and phosphorylation of RET, these RTKs merit investigation as to their roles in the biology of AGSACA and TC and their contribution to toceranib’s activity.</p>
first_indexed 2024-12-17T05:26:29Z
format Article
id doaj.art-a16c469b960f48749d237043239c2479
institution Directory Open Access Journal
issn 1746-6148
language English
last_indexed 2024-12-17T05:26:29Z
publishDate 2012-05-01
publisher BMC
record_format Article
series BMC Veterinary Research
spelling doaj.art-a16c469b960f48749d237043239c24792022-12-21T22:01:51ZengBMCBMC Veterinary Research1746-61482012-05-01816710.1186/1746-6148-8-67Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinomaUrie Bridget KRussell Duncan SKisseberth William CLondon Cheryl A<p>Abstract</p> <p>Background</p> <p>Toceranib phosphate (Palladia) has a reported objective response rate of 25% in both canine apocrine gland anal sac adenocarcinoma (AGASACA) and thyroid carcinoma (TC), with stable disease occurring in an additional 50-60% of dogs. The basis for the observed responses to toceranib is not known. The purpose of this study was to evaluate AGASACA and TC samples for the expression and activation of VEGFR2, PDGFRα, PDGFRβ, KIT and RET to assess whether dysregulation of these receptor tyrosine kinases (RTKs) may contribute to the biologic activity of toceranib.</p> <p>Results</p> <p>mRNA for VEGFR2, PDGFRα/β, KIT and RET was detected in all AGASACA samples. mRNA for VEGFR2, PDGFRα/β, and KIT was detected in all TC samples, while mRNA for RET was amplified in 10/15 samples. No phosphorylation of VEGFR2, PDGFRα/β, or KIT was observed on the arrays. However, phosphorylation of RET was detected in 54% of the primary AGASACA and 20% of TC. VEGFR2 was expressed in 19/24 primary and 6/10 metastatic AGASACA and 6/15 TC samples. KIT was present in 8/24 primary and 3/10 metastatic AGASACA and 9/15 TC samples. PDGFRα expression was noted in all tumor samples. In contrast PDGFRβ expression was found in only a few tumor samples but was evident in the stroma of all tumor specimens.</p> <p>Conclusions</p> <p>Known targets of toceranib are expressed in both AGASAC and TC. Given the observed expression of VEGFR and PDGFRα/β and phosphorylation of RET, these RTKs merit investigation as to their roles in the biology of AGSACA and TC and their contribution to toceranib’s activity.</p>http://www.biomedcentral.com/1746-6148/8/67CanineAnal sac adenocarcinomaApocrine gland of the anal sacThyroid carcinomaToceranib
spellingShingle Urie Bridget K
Russell Duncan S
Kisseberth William C
London Cheryl A
Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
BMC Veterinary Research
Canine
Anal sac adenocarcinoma
Apocrine gland of the anal sac
Thyroid carcinoma
Toceranib
title Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
title_full Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
title_fullStr Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
title_full_unstemmed Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
title_short Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
title_sort evaluation of expression and function of vascular endothelial growth factor receptor 2 platelet derived growth factor receptors alpha and beta kit and ret in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma
topic Canine
Anal sac adenocarcinoma
Apocrine gland of the anal sac
Thyroid carcinoma
Toceranib
url http://www.biomedcentral.com/1746-6148/8/67
work_keys_str_mv AT uriebridgetk evaluationofexpressionandfunctionofvascularendothelialgrowthfactorreceptor2plateletderivedgrowthfactorreceptorsalphaandbetakitandretincanineapocrineglandanalsacadenocarcinomaandthyroidcarcinoma
AT russellduncans evaluationofexpressionandfunctionofvascularendothelialgrowthfactorreceptor2plateletderivedgrowthfactorreceptorsalphaandbetakitandretincanineapocrineglandanalsacadenocarcinomaandthyroidcarcinoma
AT kisseberthwilliamc evaluationofexpressionandfunctionofvascularendothelialgrowthfactorreceptor2plateletderivedgrowthfactorreceptorsalphaandbetakitandretincanineapocrineglandanalsacadenocarcinomaandthyroidcarcinoma
AT londoncheryla evaluationofexpressionandfunctionofvascularendothelialgrowthfactorreceptor2plateletderivedgrowthfactorreceptorsalphaandbetakitandretincanineapocrineglandanalsacadenocarcinomaandthyroidcarcinoma